Skip to main content

Table 1 Baseline Participant Characteristics

From: A randomized trial of an intervention to improve use and adherence to effective coronary heart disease prevention strategies

Characteristic

Total Group (N = 160*)

Intervention Group (N = 81)

Control Group (N = 79)

Mean age

63

63

64

Female

28%

27%

28%

Race:

   

   White

86%

88%

84%

   Black

10%

10%

10%

Education:

   

   At least some college

90%

98%

82%†

Enrolled in a prescription drug plan

90%

91%

89%

Missed medicine in the last month:

   

   Less than 5% of time

92%

90%

95%

   6-25% of time

4%

4%

3%

   26-50% of time

2%

3%

2%

   51-75% of time

0%

0%

0%

   76-95% of time

1%

1%

0%

   More than 95% of time

1%

1%

0%

Have potentially modifiable CHD risk factors:

   

   Blood pressure > 140/90 (mmHg)

36%

35%

37%

   Total cholesterol/HDL ratio > 4

54%

53%

51%

   Smoker

13%

14%

13%

   Not using aspirin, but eligible for it

50%

54%

47%

Mean systolic blood pressure (mmHg)

136.9

136.2

137.6

Mean diastolic blood pressure(mmHg)

81.0

81.5

80.4

Mean total cholesterol (mg/dL)

201.1

204.9

197.1

Mean HDL cholesterol (mg/dL)

53

54.1

51.9

Mean predicted CHD risk over 10 yrs

11.3

11.2

11.4

# of possible intervention options for CHD risk:‡

   

   0

10%

12%

8%

   1

28%

28%

27%

   2

47%

40%

54%

   3

16%

20%

11%

   4

0%

0%

0%

Have self-efficacy to lower at least 1 CHD risk factor

98%

99%

96%

Are planning best evidence interventions§

27%

28%

25%

  1. Abbreviations: CHD = Coronary heart disease; HDL = high density lipoprotein
  2. * 160 participants at baseline; 3 missed both primary and follow-up study visits and 3 declined further participation after the primary study visit
  3. † Statistically different between the intervention and control groups (p < .01)
  4. ‡ This includes hypertension medicine, cholesterol medicine, smoking cessation, and aspirin
  5. §Proportion planning to do any of the following intervention options that are supported by the highest quality of evidence: hypertension medicine, cholesterol medicine, smoking cessation, and aspirin